USIBC to embark Life Sciences Executive Mission for India

The U.S.-India Business Council will embark on a Life Sciences Executive Mission to coincide with the Biotechnology Industry Organization's First Annual International Partnering Conference in Hyderabad, India from September 21-22. The mission will be led by Amgen's Dr. Romi Singh, Executive Director of Global Regulatory Affairs and Safety.

“The clinical research industry will play a vital role in fostering the growth anticipated in the Vision 2020 report. This mission will help ensure that we're laying the groundwork for increased regulatory harmonization and collaboration.”

According to the recently released "Vision 2020" report produced by ABLE and PriceWaterhouseCoopers at the request of India's Department of Industrial Policy and Promotion, the global biopharmaceutical market could be worth $319 billion by 2020. According to the report, India should aim to capture 10% of this market. The USIBC delegation, consisting of the world's leading biopharmaceutical players, will be meeting with Indian government officials and industry leaders to discuss the policies and innovation ecosystem necessary to ensure that India meets or exceeds that target.

The biopharmaceutical industry executives will be joined by several industry leaders in the clinical research space. According to USIBC President Ron Somers, "The clinical research industry will play a vital role in fostering the growth anticipated in the Vision 2020 report. This mission will help ensure that we're laying the groundwork for increased regulatory harmonization and collaboration."

The USIBC mission will also participate in several meetings of the bilateral U.S.-India High Technology Cooperation Group. The results of these meetings, focused on the regulation of biologics and biosimilars and on fighting spurious drugs, will ultimately form the basis of discussions between the U.S. and Indian governments.